Nail Psoriasis Clinical Trial
Official title:
Evaluation of the Efficacy and Safety of Indigo Naturalis Oil Extract on Psoriatic Nails
Verified date | July 2019 |
Source | Chang Gung Memorial Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to evaluate efficacy and safety of indigo naturalis oil extract in treating nail psoriasis.
Status | Completed |
Enrollment | 31 |
Est. completion date | September 2010 |
Est. primary completion date | September 2010 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 20 Years to 65 Years |
Eligibility |
Inclusion criteria: 1. adults aged between 20 and 65 years 2. received a diagnosis of nail psoriasis with at least one year history based on clinical assessment by two dermatologists and failure of topical systemic Chinese herbal anti-psoriasis therapy for fingernail psoriasis. 3. Female patients of childbearing age agreed to continue using birth control measures for the duration of the study. Exclusion criteria: 1. Patients had non-plaque (i.e., pustular, guttate, or erythrodermic) or drug-induced forms of psoriasis, total body surface involvement of more than 60% 2. a history of allergy to indigo naturalis, or with onychomycosis or any fingernail infection. 3. Patients have received systemic therapy within four weeks before enrollment 4. Patients have received phototherapy within three weeks, or topical psoriasis agents within two weeks. 5. Using medications which affect psoriasis during the study and unwillingness to comply with study protocol. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Chang Gung Memorial Hospital |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change From Baseline in Single-Hand Nail Psoriasis Severity Index (NAPSI)and in the Modified Target NAPSI for the Single Most Severely Affected Nail of Each Hand at Week 12. | The nail is divided by imaginary horizontal and longitudinal lines into quadrants. Each nail is given a score for nail bed psoriasis (0-4) and nail matrix psoriasis (0-4) depending on the presence of any of the features of nail psoriasis in that quadrant. The NAPSI score evaluates presence of signs in the nail bed (of onycholysis, splinter hemorrhages, nail bed discoloration, and subungual hyperkeratosis) and on the nail matrix (pitting, leukonychia, red spots in the lunula and nail plate crumbling) in all 10 fingernails, providing a minimal score of 0 and a maximum of 80. This study is an intra-patient side-to-side comparison, it measures nail disease on a single hand. All 5 fingers in each group were scored providing a maximum score of 40 and a minimal of 0. The modified target NAPSI score for the target nail scores severity of nail matrix and nail-bed psoriasis from 0 (no sign) to 3 (severe involvement) in each nail quadrant, providing a maximum score of 96 and a minimal of 0. | Baseline and Week 12 | |
Primary | Change From Baseline in Single-Hand Nail Psoriasis Severity Index (NAPSI)and in the Modified Target NAPSI for the Single Most Severely Affected Nail of Each Hand at Week 24. | The nail is divided by imaginary horizontal and longitudinal lines into quadrants. Each nail is given a score for nail bed psoriasis (0-4) and nail matrix psoriasis (0-4) depending on the presence of any of the features of nail psoriasis in that quadrant. The NAPSI score evaluates presence of signs in the nail bed (of onycholysis, splinter hemorrhages, nail bed discoloration, and subungual hyperkeratosis) and on the nail matrix (pitting, leukonychia, red spots in the lunula and nail plate crumbling) in all 10 fingernails, providing a minimal score of 0 and a maximum of 80. This study is an intra-patient side-to-side comparison, it measures nail disease on a single hand. All 5 fingers in each group were scored providing a maximum score of 40 and a minimal of 0. The modified target NAPSI score for the target nail scores severity of nail matrix and nail-bed psoriasis from 0 (no sign) to 3 (severe involvement) in each nail quadrant, providing a maximum score of 96 and a minimal of 0. | Baseline and Week 24 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT03209388 -
Study of the Efficacy and Safety of Topical P-3073 in the Treatment of Mild to Moderate Psoriatic Fingernail/s
|
Phase 3 | |
Completed |
NCT00581100 -
Effects of Etanercept on Nail Psoriasis and Plaque Psoriasis
|
Phase 4 | |
Completed |
NCT04580537 -
Assessing the Efficacy of Image-guided Laser-assisted Enstilar® Delivery for Treatment of Psoriatic Nails
|
Phase 2 | |
Not yet recruiting |
NCT03263624 -
Efficacy of Combined Fractional Carbon Dioxide Laser and Topical Tazarotene in the Treatment of Psoriatic Nail Disease
|
Phase 4 | |
Completed |
NCT02606760 -
Study to Evaluate the Efficacy and Safety of P-3073 Nail Solution in the Treatment of Nails Affected by Psoriasis
|
Phase 3 | |
Completed |
NCT04227288 -
A Study Evaluating the Efficacy and Tolerability of Enstilar Foam in Patients With Nail Psoriasis
|
Phase 4 | |
Withdrawn |
NCT03079973 -
Study to Evaluate the Efficacy and Safety of P-3073 Nail Solution in the Treatment of Mild to Moderate Psoriatic Fingernail/s
|
Phase 3 | |
Completed |
NCT04380597 -
Observational Study in Patients With Nail Psoriasis Treated With Enstilar® to Assess the Severity Change and the Quality of Life
|
||
Completed |
NCT03991936 -
Benefit of Placebo and Different Concentrations of Triamcinolone Acetonide in Nail Psoriasis
|
Phase 4 | |
Recruiting |
NCT05124080 -
An Investigator Initiated Open Label Study Evaluating the Efficacy and Tolerability of Oral Deucravacitinib for the Treatment of Nail Psoriasis
|
Early Phase 1 | |
Completed |
NCT03757364 -
Methotrexate in the Treatment of Distal Interphalangeal Joint Extensor Tendon Enthesopathy in Nail Psoriasis
|
||
Completed |
NCT02016482 -
A Study to Evaluate the Safety and Efficacy of Adalimumab in Subjects With Chronic Plaque Psoriasis and Nail Psoriasis
|
Phase 3 | |
Completed |
NCT02168933 -
308nm Excimer Laser for Treatment of Fingernail Psoriasis
|
N/A | |
Completed |
NCT01445886 -
Comparison of Indigo Naturalis Oil Extract and Calcipotriol Solution in Treating Psoriasis
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT05695833 -
Nd:YAG Laser and Radiofrequency in Treatment of Fingernail Psoriasis
|
N/A | |
Completed |
NCT03616561 -
Quality of Life and Ultrasonographic Assessment of Nail Psoriasis After Treatment With Apremilast (JUST Study)
|
||
Completed |
NCT02235480 -
Efficacy and Safety of Tazarotene Gel in Nail Psoriasis
|
Phase 2 | |
Not yet recruiting |
NCT06150794 -
Methotrexate Alone vs Combination With Excimer Light in Nail Psoriasis
|
N/A | |
Completed |
NCT03946826 -
A Clinical Observation on the Efficacy and Safety of Pulsed Dye Laser (PDL) in the Treatment of Nail Psoriasis
|
N/A | |
Active, not recruiting |
NCT05072886 -
Study of Efficacy and Safety of Investigational Treatment in Patients With Nail Psoriasis
|
Phase 1 |